Anti-CD20 treatment prolongs syngeneic islet graft survival and delays the onset of recurrent autoimmune diabetes

Ann N Y Acad Sci. 2008 Dec:1150:217-9. doi: 10.1196/annals.1447.032.

Abstract

Type 1 diabetes is an autoimmune disease characterized by T cell-mediated destruction of pancreatic islet beta cells. Pancreatic islet transplantation with long-term immunosuppressive drug treatment is an accepted therapeutic option for patients with type 1 diabetes suffering from disabling hypoglycemia on insulin treatment. Here we investigated the replacement of immunosuppressive drug treatment with immune tolerance establishment induced by temporary B cell-depletion therapy for islet transplantation. The result suggested that the combined therapy of B cell depletion and syngeneic islet transplantation may reverse the disease in hCD20/NOD mice.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antigens, CD20 / immunology*
  • B-Lymphocytes / immunology
  • B-Lymphocytes / physiology
  • Cell Separation
  • Diabetes Mellitus, Type 1 / immunology
  • Diabetes Mellitus, Type 1 / prevention & control*
  • Graft Survival / drug effects*
  • Graft Survival / immunology
  • Islets of Langerhans Transplantation / immunology
  • Islets of Langerhans Transplantation / methods*
  • Male
  • Mice
  • Mice, Inbred NOD
  • Secondary Prevention
  • Transplantation, Isogeneic

Substances

  • Antibodies, Monoclonal
  • Antigens, CD20